Ovarian cancer: a molecularly insidious disease

Springer Science and Business Media LLC - Tập 34 - Trang 1-3 - 2015
Delia Mezzanzanica1
1Unit of Molecular Therapies, Department of Experimental Oncology and Molecular Medicine, DOSMM, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy

Tóm tắt

In this issue of the Chinese Journal of Cancer, European, American, and Chinese experts review the current management and future perspectives of epithelial ovarian cancer (EOC), the leading cause of gynecological cancer deaths. Although major advances have been made in understanding the cellular and molecular biology of this highly heterogeneous malignancy, the survival rate of women with EOC has changed little since the introduction of platinum-based treatment as a front-line therapy. The papers describe the progress in deciphering the molecular complexity of this disease and the newly available molecular-driven therapies, which have been applied by shifting trial designs toward restricting eligibility to specific subgroups of patients rather than testing agents in unselected populations. These new trial designs provide potential opportunities for improved efficacy in targeted populations. Given the molecular complexity of this disease, patient survival may be increased by searching for new molecular prognostic/predictive signatures as well as by translating the recent insight of microRNA involvement in EOC progression into new, targeted therapies. Particular attention has been given to the issue of fertility sparing for women affected by curable diseases.

Tài liệu tham khảo

Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Randomized Controlled trial. JAMA, 2011,305:2295–2303.

Siegel R, Ma J, Zou Z, et al. Cancer statistics 2014. CA Cancer J Clin, 2014,64:9–29.

International Agency for Research on Cancer. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. Available at: http://globocan.iarc.fr.

Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature, 2011,474:609–615.

Vaughan S, Coward JI, Bast RC, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nature Rev, 2011, 11:719–725.

Shih IM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol, 2004,164:1511–1518.

Devouassoux-Shisheboran M, Genestie C. Pathobiology of ovarian carcinomas. Chin J Cancer, 2015,34:50–55.

Kurman RJ, Shih IM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol, 2010,34:433–443.

Della Pepa C, Tonini G, Pisano C, et al. Ovarian cancer standard of care: are there real alternatives? Chin J Cancer, 2015,34:17–27.

Banerjee S, Kaye SB. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clin Cancer Res, 2013,19:961–968.

Bookman MA, Gilks CB, Kohn EC, et al. Better therapeutic trials in ovarian cancer. J Natl Cancer Inst, 2014,106:dju029.

Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomized phase 2 trial. Lancet Oncol, 2014,15:852–861.

Gourley C, McCavigan A, Perren T, et al. Molecular subgroup of high grade ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab. J Clin Oncol, 5s, 2014,32 suppl: abstr 5502.

Winterhoff BJN, Kommoss S, Oberg AL, et al. Bevacizumab may differentially improve survival for patients with the proliferative and mesenchymal molecular subtype of ovarian cancer. J Clin Oncol, 32:5s, 2014,32 suppl:abstr 5509.

Cheaib B, Auguste A, Leary A. The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges. Chin J Cancer, 2015,34:4–16.

López-Guerrero JA, Romero I, Poveda A. Trabectedin as an emerging strategy in recurrent platinum-sensitive ovarian cancer treatment. Chin J Cancer, 2015,34:41–49.

Sun Y, Guo F, Bagnoli M, et al. The key nodes of a microRNA network associated with integrated mesenchymal subtype of highgrade serous ovarian cancer. Chin J Cancer, 2015,34:28–40.

Sigismondi C, Papaleo E, Viganò P, et al. Fertility preservation in female cancer patients: a single center experience. Chin J Cancer, 2015,34:56–60.

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Tập 34

1-3

Thông tin tác giả